FDA approves first-ever eye drops that corrects age-related vision loss – clinical daily news



The Food and Drug Administration has approved the first eye drops to treat presbyopia, a form of progressive age-related vision loss that often results in the need for reading glasses.

Vuity (pilocarpine HCl ophthalmic solution) 1.25% helps adjust pupil size. It contracts the iris sphincter muscle, constricting the pupil and improving depth of field. It improves near vision without affecting distance vision, drug maker Allergan, an AbbVie company, announcement Saturday, October 30.

After 30 days of daily use, the medicine will start to work in as little as 15 minutes and results can last up to 6 hours. Common side effects found in clinical trials for the drug are headaches and eye redness, the company said.

“I am particularly encouraged by the rapid onset of action and the duration of effectiveness of VUITY to improve near and intermediate vision without affecting distance vision with one drop per day, especially for people with mild to presbyopia. moderate, ”said George O. Waring IV, MD, of the Waring Vision Institute, SC, who participated in the clinical trials.

The drug has been tested in relatively young elderly people, aged 40 to 55 years.

Presbyopia is estimated to affect nearly half of America’s adult population starting around the age of 40, and occurs when eye lenses lose flexibility, making it more difficult to focus, AbbVie said.

Related stories:

Eye drops corrects loss of vision at the end of life in a trial; Allergan reports patient feedback

More reading glasses? Eye drops for elderly vision loss lands on FDA desk



Comments are closed.